Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

NCT01696500 is registered in ClinicalTrials.gov with Nihon Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT01696500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01696500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
June 30, 2014
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stevens-johnson syndrome, toxic epidermal necrolysis